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ABSTRACT Immune cells responsible for inflammation development are involved in tissue damage caused by 
wounding and various pathologies. Control of immune cell activation could be of significant benefit for re-
generative medicine and the treatment of patients with autoimmune and degenerative diseases. It is a proven 
fact that MCSs (multipotent mesenchymal stromal cells) are capable of suppressing immune responses via the 
inhibition of dendritic cell maturation and via the restraining of the T, B, and NK cell function in the course of 
autoimmune diseases and various forms of inflammation. MSCs can be isolated easily from almost every type 
of tissue or organ and subsequently expanded in vitro. These cells are self-renewable and can be differentiated 
into various cell types of mesenchymal lineage. The current review contains a collection and critical analysis of 
data regarding the molecular mechanisms responsible for cross-talk between immune cells and MSCs. Some of 
these mechanisms can be used for the development of new practical approaches for the treatment of autoim-
mune diseases.
KEYWORDS immune system; multipotent mesenchymal stromal cells; inflammation; autoimmune disease; re-
generation; immune suppression.
ABBREVIATIONS MSCs – multipotent mesenchymal stromal cells; CD – cluster of differentiation; SDF-1 – stem 
cell-derived factor-1; CXCR4 C-X-C chemokine receptor 4; VEGF – vascular endothelial growth factor; IGF-1 – 
insulin-like growth factor-1; BDNF – brain-derived neurotrophic factor; TGF-β – tumour growth factor; BMP– 
bone morphogenetic protein; IL-10 – interleukin-10; TNF-α – tumour necrosis factor; NK – natural killers; DC 
– dendritic cells; IFN-γ – interferon gamma; MHC – major histocompatibility complex; IDO – indoleamine-2,3-
dioxygenase; PGE2 – prostaglandin E2; ICAM – intercellular adhesion molecule; VCAM – vascular cell adhe-
sion protein; IL-1β – interleukin-1 beta; GVHD – graft versus host disease; EAE – experimental autoimmune 
encephalomyelitis; TLR – Toll-like receptor; HLA-G5 – non-classical molecule of histocompatibility complex 
class I antigen, G5 isoform.
INTRODUCTION: GENERAL CHARACTERISTICS OF MSC
Multipotent mesenchymal stromal cells (MScs) were 
originally characterized in the pioneering study of 
Friedenstein et al. in 1971 [1]. It was shown in that study 
that a heterogeneous fraction of cells bearing morpho-
logical resemblance to fibroblasts can adherently grow 
in a culture, tolerate numerous passages, and be isolated 
from bone marrow cells. MScs express a set of markers 
on their surface (suggesting their mesenchymal origin) 
and are capable of differentiating into adipose, bone, 
and cartilage cells [1] and, to a lesser extent, into other 
cell types. the set of markers characteristic of MScs 
includes cD105, cD166, cD54, cD90, cD55, cD13, 
cD73, Stro-1, and cD44; meanwhile, the surface of an 
MSc does not contain the hematopoietic markers cD14, 
cD45, cD34 and СD133 [2]. It was subsequently ascer-
tained that cells with similar properties can be isolated 
not only from the bone marrow, but also from other 
sources (in particular, from adipose tissue) [3].
A detailed study of the properties of MScs has dem-
onstrated that self-sustaining clones can be derived 
from a fraction of single cells [4]. MSc populations from 
different sources can be passaged, as opposed to ter-
minally differentiated cells; culture heterogeneity is 
strongly passage-dependent [5]. the rates of growth 
and division of MScs in a culture gradually decrease 
due to telomere shortening at chromosome ends [6, 7].
the absence of any “reliable” surface markers ren-
ders the in vivo identification and study of MScs ex-
tremely difficult; therefore, we have yet to determine 
whether MScs are an artifact of in vitro isolation and 
cultivation of a complex cell mixture, or whether in-24 | ActA nAturAe |  VOL. 4  № 1 (12)  2012
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deed this population exists in the organism. Opinions 
concerning the nature of MSc differ considerably. It 
has been clearly demonstrated in a number of studies 
that MScs resemble fibroblasts (another stromal cell 
type) in terms of many characteristics [8]. the authors 
of a number of studies compare MScs with the popula-
tion of pericytes; i.e. vascular endothelium-associated 
cells that carry a set of markers on their surface, dif-
fering from that in MScs to only a small extent [9, 10]. 
nevertheless, the interest of researchers and medical 
investigators in MScs is primarily a result of the unique 
properties of MScs, which make these cells a promising 
object for cell and gene therapy; issues of their origin 
and philogeny ultimately fade into insignificance.
MSCS MIGRATE TO THE LESION LOCUS
When transplanted into animals with induced lesions 
or internal pathologies, MScs are capable of migrat-
ing to the lesion site or to the inflammation focus. this 
discovery was confirmed by the results of experiments 
devoted to the systemic transplantation of variously 
labelled cells into recipients with the above-mentioned 
lesions (fluorescent protein-expressing cells were used, 
cells from male donors were transplanted into female 
recipients, human cells were used for heterologous 
transplantation into mice or rats) [11–15]. After a short 
period of time, the transplanted cells can be detected 
at the lesion site. MSc migration to the lesion (inflam-
mation) site depends on chemokines, which is indirectly 
evidenced by the results of an analysis of chemokine 
receptor expression by MScs. these cells express a 
wide range of chemokine receptors [16–18]. the con-
tribution of most of them to the directed migration of 
MScs has not yet been ascertained; however, it has 
been shown that SDF-1 and its receptor called c-X-c 
chemokine receptor type 4 (cXcr4) play the key role 
in this process. the cXcr4 level increases significantly 
in cells under stress conditions [16, 19, 20]. Disruption 
of signaling through this receptor using biochemical or 
genetic methods impairs MSc migration to the lesion/
inflammation sites [19]. cXcr4 plays an essential role, 
since this receptor is also responsible for the retention 
of the hematopoietic stem cells in the bone marrow. 
Stem cells may leave the bone marrow as a result of 
systemic lesions due to the competition between MScs 
and hematopoietic cells for the cXcr4 ligand – SDF-1 
[21, 22]. For some time it was believed that MSc mi-
gration to the damaged tissue was indicative of active 
participation of these cells in tissue repair and regen-
eration. Additional studies of the behavior and migra-
tion of MScs upon heterological transplantation clearly 
show that the proportion of MScs that reach the lesion 
site post-transplant is very low. Moreover, the cells do 
not remain in the tissue and soon disappear. In this con-
text, the initial assumption that the major role of MScs 
was the direct replacement of the damaged-tissue cells 
through differentiation was dismissed[10]. Instead, the 
hypothesis that MScs can facilitate the division and 
differentiation of stem and precursor cells, thus regu-
lating their recruitment and survival upon stress con-
ditions and injuries by secreting soluble factors, was 
proposed [23]. therefore, it was suggested that MScs 
serve as a mobile supplier of the factors necessary for 
tissue repair and regeneration.
SECRETORY POTENTIAL OF MSCS AND 
REGENERATIVE PROCESSES
MScs possess a unique property, which is secretion of 
a wide range of biologically active molecules, such as 
growth factors, cytokines, hormones, and low molecu-
lar weight mediators, which regulate the key physi-
ological processes [23]. Factor production and the ability 
to produce/destroy the cell matrix underlie the physi-
ological effect that MScs have on the damaged tissue 
[24–26]. It has been demonstrated that the production 
of soluble factors by MScs can support tissue cells, in 
addition to resident stem and precursor cells under in-
flammatory conditions and hypoxia, which inevitably 
accompany wound and pathological lesions [27–29]. It 
has been proven that the secretion of proangiogenic 
factors, such as VeGF, IGF-1, etc., by McSs accelerates 
vascular growth and maturation at the lesion site [30–
32]; the secretion of neurotrophic factors (in particular 
BDnF) facilitates the recovery of damaged neurons 
[33–35]; and the secretion of morphogenic proteins of 
the tGF-β family facilitates bone and cartilage tissue 
repair after a fracture [36–38] (Fig. 1). It is very likely 
that immediate contact with the surrounding cells and 
structures (microenvironment) also plays a significant 
role in the regenerative function of MScs; however, 
few experimental studies exist to support this idea.
IMMUNE CELLS IN TISSUE DAMAGE AND REGENERATION
When discussing the specific conditions accompanying 
tissue healing and repair processes, specific attention 
should be focused on the contribution of immune cells. 
It is a known fact that the immune system of mammals, 
including the human immune system, is a complex pro-
tective mechanism consisting of numerous types of cells 
that fight against infectious agents of different origin. 
the oldest immunity segment in terms of its evolution is 
represented by the cells responsible for recognizing for-
eign molecules and providing an immediate response to 
their presence [39]. these cells use molecular signalling 
to “pass the baton” to the adaptive immunity cells re-
sponsible for the development of the powerful immune 
response that is typically accompanied by the release of 
significant amounts of cytotoxic and proinflammatory reVIeWS
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molecules [40, 41]. unfortunately, it is not easy to control 
this powerful and complex mechanism and accurately 
measure the adequate strength and direction of the at-
tacks. the immune response is accompanied by acute or 
chronic damage to tissues and organs [39].
there exists a quite definite order of immune system 
reactions that accompany any damage to internal or-
gans, injury, or infection. tissue-resident mast cells, den-
dritic cells (Dc), and macrophages act as damage sensors 
[38]. they initiate the cascade of immune reactions via 
the release of proinflammatory cytokines, chemokines, 
and factors that facilitate the migration and stimulation 
of other cell types. cytokines and adhesion molecules, 
which ensure rapid neutrophil accumulation at the le-
sion site, play the key role in this process [39]. In turn, cy-
tokine and chemokine production by neutrophils causes 
macrophage migration and the release of additional 
proinflammatory cytokines, such as IFn-γ and tnF-α 
[40]. the secretion of larger amounts of inflammatory 
cytokines recruits t and B cells by accelerating their 
activation and maturation. these cells accumulate at 
the lesion site, thus enhancing inflammation due to the 
production of new doses of cytokines and proinflamma-
tory factors, often resulting in an undesired lesion and 
subsequent cell death in the surrounding tissue [41–44]. 
In turn, the inflammatory response initiates the molec-
ular mechanisms that suppress activation and division 
of immune system cells. these mechanisms include an 
increase in sensitivity of the activated cells to apoptosis, 
an upregulation of the expression of anti-inflammatory 
cytokine (IL-10 and tGF-β) receptors on the surface of 
immune cells, production of these cytokines by activat-
ed cells, the elevated production of negative coactiva-
tor molecules, the activation of regulatory cells and an 
increase in their number [45–47]. All these events re-
sult in the completion of the acute phase of the immune 
response, the death of injured and activated cells, and 
the phagocytosis of dead cells and their fragments by 
professional phagocytes [48]. Meanwhile, the produc-
tion of such factors as tGF-β causes fibrotic changes in 
the tissue structure and facilitates the replacement of 
the original tissue with fibrin and connective tissue [49, 
50]. A significant role belongs both to the cells of the sur-
rounding tissue and to vascular endothelial cells, which 
by secretion and release of factors from the extracellular 
matrix direct the migration of particular effector cells 
into the lesion site [51]. to summarize, it should be em-
phasized that cells of the immune system are involved 
into all phases of the regenerative processes in tissues 
(Fig. 1). the participation of these cells actually defines 
the timeline and efficiency of the healing. Furthermore, 
the level of tissue inflammation and lesion considerably 
depends on the interaction between tissue cells and cells 
of the immune system.
MSC ANTIGEN PRESENTATION
taking into account the secretory potential of MScs 
and the effect on the microenvironment at the lesion 
site, the positive effect of MScs in different models of 
tissue regeneration can (at least to some extent) be ac-
counted for by their influence on cells of the immune 
system (Fig. 1). In this context, the immunological 
properties of MScs have been studied rather thor-
oughly. unfortunately, this does not apply to the mo-
lecular mechanisms being responsible for these prop-
erties. In immunological terms, MScs strongly differ 
from body cells by their almost complete inability to 
be recognized by the immune system due to their phe-
notypic features [52, 53]. As a result of this property, 
MScs are a promising object for application in trans-
plantology, since it allows one to bypass the problem of 
immunological compatibility. In comparison with other 
cell lineages, MScs express an extremely insignificant 
amount of MHc I and MHc II molecules and carry no 
costimulatory molecules cD40, cD80, or cD86, which 
are required for t cell activation [54]. Meanwhile, MHc 
expression recovers during the differentiation, result-
ing in the recognition and destruction of the MSc prog-
eny by the recipient’s immune system cells [55]. MScs 
do not cause allogeneic mixed lymphocyte reaction in 
completely heterologous cultures [54]. MSc-mediated 
Tissue lesion
Primary reaction of mastocytes 
and macrophages, attraction  
of neutrophils
Macrophage migration  
to the lesion site;  
macrophage activation 
Activation  
of the adaptive immunity 
cells (T and B cells)
Termination of the active 
inflammation phase,  
vessel growth
Fibrosis and tissue  
remodeling
MSCs –  
mesenchymal  
stromal cells
Fig. 1. Main events following damage to inflammatory/
wound tissue and the involvement of immune cells. The 
effect of MSCs on particular steps is shown with arrows in 
the case of positive influence; and with blunt-end arrows, 
in the case of negative (inhibitory) influence.26 | ActA nAturAe |  VOL. 4  № 1 (12)  2012
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expression of MHc may vary depending on culturing 
conditions. In particular, MScs activate the expression 
of MHc genes in the presence of small IFn-γ concen-
trations, which results in their capability of antigen 
presentation (in vitro). High doses of IFn-γ do not have 
this effect [56].
It has recently been demonstrated that MScs can 
suppress the immune response by inhibiting nK mat-
uration, suppressing the functions of t and B lym-
phocytes and natural killer (nK) cells [57–60].
MSC IMMUNOREGULATION INVITRO
Most of the data on the immunological properties of 
MScs has been obtained as a result of experiments on 
in vitro cocultivation or the joint incubation of MScs 
and cells of the immune system. In these types of ex-
periments, human blood leukocytes, or individual 
populations (e.g., t cells), were placed into the MSc-
containing culture following activation. the effect of 
MScs on the immune cells or, vice versa, the effect of 
immune cells on MScs was then determined by meas-
uring the cell division rate, the metabolic activity, the 
level of activation marker expression, the apoptosis lev-
el, and the secretion of cytokines and growth factors, 
etc. the following major regularities and mechanisms 
which have an impact on the results of the interaction 
between MScs and cells of the immune system have 
been revealed [57–60] (Fig. 2, 3). It turns out that MScs 
have different effects on different types of cells of the 
immune system. naive (non-activated) t cells survive 
and divide in culture better in the presence of MScs 
and MSc culture supernatants. Meanwhile, the activat-
ed t cells are susceptible to immunosuppression in the 
presence of MScs. It has been ascertained that MScs 
reduce the proliferative potential of t cells, the expres-
sion of activation markers and coactivatory molecules, 
and their ability to secrete proinflammatory cytokines, 
such as IFn-γ and tnF-α [58, 59, 61]. A similar effect 
was also observed for dendritic cells. After coculturing 
human or murine dendritic cells with MScs, with Dc 
maturation characterized by the expression of the mol-
ecules of the major histocompatibility complex on the 
cell surface, the capability of processing and represent-
ing protein antigen peptides to cD4 and cD8 t cells de-
creased in comparison to the control cocultures [60, 62, 
63]. the effect also consisted in the reduction of the lev-
el of costimulatory molecules required for productive 
antigene presentation for t cells. Moreover, MScs have 
a negative impact on the activation of immune cells of 
other types (in particular, nK [64, 65] and B cells [57, 
66, 67]) in a culture. Inhibition of division and secretion 
of various immunoglobulins (IgA, IgM, IgG), as well 
as a decrease in chemokine receptor (cXcr4, cXcr5, 
cXcL12) expression manifesting itself in the suppres-
sion of cell chemotaxis, is observed for B cells [57, 64]. A 
set of factors secreted by MScs have a negative impact 
on antigen production by plasma cells as a result of the 
activity of the ccL2 and ccL7 ligands that are formed 
as a result of the activity of matrix metalloproteinases 
being released from MScs [65] (Fig. 3).
In early studies, the influence of MScs on immune 
cells was determined in a blood mononuclear cell cul-
ture activated by preliminary incubation with anti-
bodies against a t cell receptor or with nonspecific 
activators of the immune response (hemagglutinin, 
superantigens) [57–60]. For this assays t cells are the 
most convenient cell population, since it is the most 
abundant and the best characterized fraction of cells 
of the immune system. It is for this reason that the 
mechanism of the MSc effect on t cells has been stud-
ied appreciably well. It has been ascertained from the 
experiments on the MSc effect on activation and the 
effector function of t cells that only MScs that were 
pre-incubated with activated t cells display immu-
nosuppressive properties [68] (Fig. 2). Furthermore, 
incubation of MScs with individual, purified proin-
flammatory cytokines (e.g., with IFn-γ) results in the 
emergence of these properties in MScs (and MSc 
culture supernatants) [69–72]. this fact implies that 
cytokines stimulate MScs, and this “activation” un-
derlies the manifestation of immunosuppressive prop-
erties by MScs (Fig. 2).
ACTIVATION OF IMMUNOSUPPRESSIVE PROPERTIES 
OF MSC REqUIRES PRELIMINARY STIMULATION OF 
MSC WITH PROINFLAMMATORY CYTOKINES
Which cytokines are critical for the manifestation of 
MSc’s immunosuppressive properties? the answer to 
this question has been obtained using blocking antibod-
TLR 
IFN-γ
TNF-α
IL-1 
iNOS/NO
IDO 
PGE2
Fig. 2. Schematic representation of the key factors in-
volved in immunosuppression stimulation by MSC (on the 
left) and soluble effector molecules mediating the inhibi-
tory effect of MCS on T cell function (on the right).reVIeWS
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ies against various proinflammatory cytokines in cocul-
tures of MScs and activated t cells [69–72]. the use of 
this approach has demonstrated that the neutralization 
of IFn-γ, and decrease in the level of the IFn-γ receptor 
by the over-expression of micrornAs in MScs, which 
interfere with the mrnA of one of its subunits, and the 
use of MScs from IFn-γ receptor knockout mice result 
in a considerable reduction in the ability of these modi-
fied MScs to suppress t-cell activation in a culture [69]. 
An alternative pathway for MSc activation by proin-
flammatory cytokines requires simultaneous partici-
pation of several proteins, in particular IFn-γ, tnF-α, 
and IL-1β. the requirement in these cytokines has 
been confirmed in in vitro experiments with blocking 
antibodies to the corresponding cytokines. It is worth 
noting that the blockage of any one or two different cy-
tokines (pairwise) allowed a negligible restriction of the 
immunosuppressive properties of MScs in the culture 
[69]. Only the simultaneous blocking of all three factors 
resulted in a pronounced physiological effect.
MOLECULAR MECHANISMS OF MSC-
MEDIATED IMMUNOREGULATION
It has been demonstrated, by a study of the molecular 
differences between “regular” and activated MScs, 
that the expression of a number of genes, controlling 
suppression mechanisms, is triggered after treatment 
of MScs by cytokines (Fig. 2). In particular, the level 
of indolamine-2,3-dioxygenase (IDO) in MScs increas-
es as a result of the action of proinflammatory cytok-
ines [73]. It was revealed in earlier studies that IDO 
is a negative regulator of the t cell function. the se-
creted form of this enzyme is believed to diminish the 
level of free tryptophan (rapidly dividing activated 
t cells require large amounts of this amino acid) [74]. 
Moreover, tryptophan catabolite kynurenine, which is 
a product of IDO enzyme activity, also suppresses t-
cell activation [74]. the experiments, in which a syn-
thetic IDO inhibitor or MScs from IDO-deficient mice 
was used, lend further credence to the significant role 
of this protein in MSc-mediated immunosuppression 
[69, 74, 75].
An alternative pathway of MSc activation based 
on simultaneous stimuli from IFn-γ, tnF-α, and IL-
1β has also been ascertained at the molecular level 
and relies mainly on a considerable increase in the 
expression of the iNOS (inducible nO synthase) gene 
by MScs. inOS is an enzyme responsible for nO pro-
duction by cells under stress conditions. the level of 
iNOS gene transcription under normal conditions is 
extremely low. the level of iNOS is known to signifi-
cantly increase in many cells of the immune system 
under the action of cytokines and other stress factors 
[76]. An increase in the level of inOS in MSc upon 
activation may attest to the fact that these cells en-
hance nO production. According to the existing data, 
the effect of nO on stimulated t cells consists in the 
suppression of cell division, cytokine secretion, and 
presumably, in an increase in the level of cell death. 
It has been shown by using inhibitors and inOS-de-
ficient MScs that inOS or nO activity is required for 
MScs to be able to manifest their immunosuppressive 
properties [76].
It is interesting to note that recently obtained data 
appears to indicate that various immunosuppressive 
mechanisms may depend on the presence/absence of 
intercellular contacts. In the case of contact coculti-
vation of MScs and activated t cells, a predominant 
increase in the level of tnF-α (but not IFn-γ) was 
observed in the system. therefore, the immunosup-
pression was predominantly inOS-dependent. On the 
other hand, the use of the contactless model resulted in 
the initiation of the alternative program that required 
IFn-γ production and, therefore, used nO production 
for immunosuppression [69].
Cytokines, 
chemokines, 
TLR ligands
Neutrophils
Dendritic cells MSCs
Regulatory  
T cells
B cells CD4+  
T cells
CD8+  
T cells
Professional  
killers
IDO
PGE2
TGF-β
NO 
HLA-G 
Fig. 3. Spectrum of MSC-mediated immunosuppression 
cellular targets. MSC immunosuppression inducers are 
presented in the frame on the left-hand side, the main 
molecules – mediators of suppression – on the right-hand 
side. MSCs induce neutrophil apoptosis, inhibit dendritic 
cell maturation and secretion of proinflammatory cytokines 
(IFN-γ, IL-12, TNF-α), slow down proliferation and B-cell 
differentiation towards plasma cells, decrease immu-
noglobulin secretion, limit division of NK, CD4 and CD8 T 
cells, and limit the secretion of proinflammatory cytokines 
and the maturation of cytotoxic T cells from CD8 T cells. 
At the same time, MSCs stimulate IL-10 production by 
dendritic and regulatory T cells and boost expansion of 
regulatory T cells. The arrows indicate the positive effect 
of MSCs on cell function, whereas the blunt-end arrows 
indicate the negative effect of MSCs.28 | ActA nAturAe |  VOL. 4  № 1 (12)  2012
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ALTERNATIVE MECHANSIMS OF MSC-
MEDIATED IMMUNOSUPPRESSION
the mechanisms responsible for the MSc-mediated 
neutralization of the activation of the cells of the im-
mune system are not confined to only IDO and nO se-
cretion. It has been shown that MScs permanently ex-
press the inducible enzyme cyclooxygenase-2 (cOX-2), 
which is responsible for the synthesis of prostaglandin 
e2 (PGe2) from arachidonic acid. PGe2 is a lipid that 
negatively affects t cell activation. Incubation of MScs 
in the presence of blood lymphocytes results in a con-
siderable increase in the PGe2 level in a culture [59, 75, 
77, 78]. this may imply interaction between MScs and 
t cells, leading to the enhanced synthesis of immuno-
suppressor molecules. Incubation of MScs in the pres-
ence of IFn-γ and tnF-α causes a boost in the cOX-2 
expression level and PGe2 secretion, thus attesting to 
the fact that the production of this regulatory molecule 
can be controlled by the inflammation level [77]. the 
introduction of PGe2 inhibitors into a mixed culture 
consisting of t cells and MScs resulted in a significant 
decrease in the immunosuppression level [77, 78].
It has been demonstrated that when incubated with 
lymphocytes or proinflammatory cytokines, MScs se-
crete enhanced levels of IL-10 and tGF-β; anti-inflam-
matory cytokines that have a negative effect on the ac-
tivation and division of t cells. the immunosuppressive 
effect that has been observed in vitro in the absence of 
antibodies can be partially eliminated by blocking an-
tibodies against these cytokines [79]. It is believed that 
the secretion of IL-10 and tGF-β by activated MScs 
accelerates the expansion of regulatory t cells, a minor 
population of cD4 lymphocytes, which are powerful 
negative immune response regulators, rather than just 
having a direct impact on t cells [80].
the nonclassical molecule of the histocompatibility 
complex class I antigen, G5 (HLA-G5), is another solu-
ble factor that presumably participates in the MSc-
mediated regulation of the immune response. Molecules 
of this type play a significant role in the establishment 
of immunological tolerance during pregnancy. the 
soluble HLA-G5 isoform is secreted by MScs in the 
presence of contacts between MScs and t cells in het-
erologous mixed cultures. HLA-G5 suppresses t cell 
proliferation and the cytotoxic properties of nK cells; 
simultaneously, it accelerates the division of regulatory 
t cells [65].
It has recently been established that MScs express a 
set of toll-like receptors (tLr), which are responsible 
for the recognition of the molecular patterns of vari-
ous pathogens and innate immunity cell activation [81]. 
A MSc culture expresses a whole set of tLr (tLr1–
tLr8) [82]. Stimulation of MScs by incubating them 
with ligands of various tLr (such as LPS) results in the 
translocation of the nF-κB transcription factor to the 
nucleus and activation of the program, which simulta-
neously enhances the immunosuppressive properties 
of MScs and increases IL-6 secretion in most cases [83, 
84]. An increase in MSc activity upon tLr ligation can 
be easily accounted for by the fact that signal trans-
duction pathways from the IFn-γ receptor and tLr 
intersect [83, 84]. thus, the effect of tLr ligation may 
result (similarly to that for IFn-γ) in increased secre-
tion of PGe2 and IDO [81].
the aforementioned mechanisms of MSc activation 
and immunosuppression are mediated by soluble fac-
tors. Meanwhile, mechanisms of MSc-mediated sup-
pression of the immune response that depend on inter-
cellular contacts have been described. One of the most 
well studied examples is the cell adhesion molecules 
IcAM-1 and VcAM-1 [85, 86], whose level on the sur-
face of an MSc increases significantly in the presence 
of inflammation factors. these molecules are responsi-
ble for directed leukocyte migration and their penetra-
tion of the walls of blood vessels. It has been shown that 
an enhancement of the MSc-mediated expression of 
IcAM-1 and VcAM-1 is one of the possible immuno-
suppressive mechanisms, since the use of blocking an-
tibodies against these molecules has reduced the level 
of MSc-mediated immunosuppression in a culture [85]. 
the results of experiments using cultures were sup-
ported by the data of in vivo experiments, in which 
MScs with the IcAM-1 and VcAM-1 genes knocked 
out were used for immunosuppression [85]. unfortu-
nately, unambiguous interpretation cannot be made 
of the results of these experiments, since the nonspe-
cific contribution of the genetic defect to cell mobility 
cannot be distinguished from the direct contribution of 
IcAM-1 and VcAM-1 to the suppression of the t cell 
function.
MSC-MEDIATED IMMUNOSUPPRESSION INVIVO
the ability of MSc to suppress the immune response 
in the context of the entire organism in vivo was first 
detected during skin grafting experiments on monkeys. 
transplanted MScs decelerated the development of the 
immune response to the graft [68]. Moreover, it turned 
out that MScs can be used in case of severe GVHD re-
action (graft versus host disease). the transplantation 
of MScs to mice, in which the lethal GVHD reaction af-
ter bone marrow transfer had been observed, enhanced 
their survival rate [87, 88]. At the time of writing, the 
mechanisms responsible for the improvement in clinical 
presentation have not been reliably determined; they 
have been only partially characterized in additional 
experiments using animals. thus, it has been demon-
strated that IFn-γ-deficient t cells are unsusceptible to 
MSc-mediated suppression in the GVHD model. In this reVIeWS
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system, the pre-activation of MSc by IFn-γ resulted in 
a fivefold increase in the immunosuppressive proper-
ties of MScs as compared with those of the control cells 
[87–90].
It is tempting to use the immunosuppressive effect 
of MScs upon human autoimmune diseases, such as 
diabetes mellitus, arthritis, multiple sclerosis, and sys-
temic lupus erythematosus. In the experimental au-
toimmune encephalitis (eAe) model, an analogue of 
multiple sclerosis in mice, systemic transplantation of 
MScs to the affected mice prevented the development 
of inflammatory infiltrates (t and B cells, macrophag-
es) and that of the demyelination process in the cnS; 
moreover, it reduced the response of t cells to MOG 
peptides which originate from myelin [91]. the medium 
in which MScs had been cultured suppressed the acti-
vation of cD4+ t cells under eAe conditions by reduc-
ing StAt-3 protein phosphorylation [92]. Infiltration of 
cD4+ t cells into the spinal cord of MSc-transplanted 
mice and the level of proinflammatory tnF-α and IL-
17 cytokines were reduced [91]. In another study, MSc 
transplantation from Balb/c mice to B57BL/6 recipi-
ents with pronounced eAe symptoms caused allevia-
tion of symptoms, such as reduction in the infiltration 
of immune cells in the cnS and a decrease in the blood 
level of IFn-γ and IL-17 cytokines [93].
In the collagen-induced arthritis mouse model, sys-
temic transplantation of MScs from human adipose 
tissue considerably reduced the probability of disease 
progression and its severity. the levels of inflammation 
and th1-type immune response significantly decreased. 
the injection of MScs resulted in the suppression of 
the expansion of the antigen-specific cells synthesizing 
IFn-γ and IL-17 [94]. Moreover, the enhanced secre-
tion of anti-inflammatory IL-10 cytokine in the drain-
ing lymph nodes adjacent to the inflamed joints, and an 
increased number of cD4+cD25+Foxp3+ regulatory 
t cells were observed [94]. MScs responded to collagen 
by suppressing the in vitro activation and division of t 
cells obtained from patients with rheumatoid arthritis 
and enhancing IL-10 secretion by t cells [95]. Further-
more, MScs stimulated the formation of regulatory t 
cells capable of suppressing the response of t cells to 
collagen and reducing the level of the enzymes that 
destroy the intercellular matrix in synovial cells [95]. 
However, the results of an independent study using an 
induced arthritis model demonstrated that transfer of 
an specific subpopulation of MScs expressing the Flk-1 
marker, on the contrary, results in enhanced arthrit-
ic manifestations due to increased IL-6 secretion and 
th17-type differentiation [96].
In the case of acute renal failure, the introduction 
of MScs led to a recovery of renal function through a 
reduction in the level of proinflammatory cytokines 
(IL-1β, tnF-α, IFn-γ) [97]. the participation of MScs 
in the regulation of the progression of fibrosis has been 
studied in a case of acute renal failure in rats. Along 
with the decrease in the IL-6 and tnF-α levels, the in-
troduction of MScs resulted in a reduction in fibrotic 
changes and recovery of the renal function. Moreover, 
an enhancement of the level of anti-inflammatory cy-
tokines was observed [98]. In an experimental model of 
pulmonary fibrosis, the level of lung inflammation was 
reduced by the introduction of MScs, presumably due 
to the secretion of a IL-1 receptor antagonist [99]. upon 
autoimmune diabetes mellitus type 1, disease progres-
sion in prediabetic nOD mice was checked through the 
allogenic transfer of McSs, which enhanced the type II 
immune response [72, 99, 100]. the prevention of β-cell 
destruction, followed by the progression of diabetes, 
was achieved through a single intravenous injection 
of MScs; this can be accounted for by the induction of 
regulatory t cells [99, 100]. When introduced to rats 
with streptozotocin-induced β-cell damage, culture-
expanded bone marrow MScs migrated to the pancre-
atic gland, increased the level of insulin secretion, and 
facilitated the normalization of the level of blood glu-
cose [101]. Furthermore, an increase in the PDX-1 and 
insulin levels in the Langerhans islets was observed, 
which assumes β-cell activation in mice receiving MScs 
[101].
CONCLUSIONS
In conclusion, it should be noted that reassuring data 
concerning the potential in using MScs and drugs 
based on the factors secreted by them in the therapy 
of autoimmune diseases and regenerative medicine 
is already available. the data above provide convinc-
ing evidence that the immunosuppressive potential of 
MScs can be enhanced by incubating the cells with in-
flammation factors and cytokines. Moreover, there is a 
possibility of obtaining genetically modified MScs with 
improved immunosuppressive characteristics. Howev-
er, it should be remembered that the infeasibility of 
strict control of the state of MScs in a culture and the 
insufficiently proved genetic stability of these cells ob-
struct the implementation of MSc-based cell technolo-
gies. the accumulation of data on the ability of MSc 
to support and accelerate tumor growth by secreting 
factors that positively impact tissue regeneration is an-
other major reason for concern [102]. 
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